To develop automated cell enrichment and cancer diagnostic platforms for high-end applications in biomedicine. We will focus on steady optimization for unmatched quality levels and high expectations. Our technology will be used by our customers and by ourselves to expand the knowledge of liquid biopsy for circulating tumor cells.
Our innovations will challenge the technological problem of rare tumor cell liquid biopsy opening doors
for use in clinical practice. Our creativeness will have an impact on patient benefit in costs, accessibility and treatment success.
Leveraging our advancement in cell separation technology and the core competency in biomarker clinical translation in partnership with leading clinical institutions in compliance with state of the art clinical standards.